LTP·01learntopeptide
Healing & repairEvidence B3 cited

Thymopentin

aka TP-5 · Timopentin · thymopoietin fragment 32-36

A synthetic pentapeptide representing the active site (amino acids 32-36) of thymopoietin. Promotes T-cell differentiation and immunomodulation without the instability of full-length thymopoietin.

Molecular wt
679.8g/mol
Formula
C30H49N9O9
CAS
69558-55-0
Half-life
30 min
clinical
Tmax
30 min
Route
Subcutaneous injection
PubChem
451417

Sequence

One-letter5 residues

RKDVY

Three-letter

Arg-Lys-Asp-Val-Tyr

Read this before quoting the sequence
Synthetic pentapeptide corresponding to residues 32-36 of thymopoietin. Free acid, no acetylation or amidation.
Source ↗

Mechanism of action

Thymopentin (TP-5) mimics the biologically active region of thymopoietin, binding to T-cell precursors and promoting their differentiation into mature T-cells. It enhances CD4+ T-helper cell function, modulates cytokine production (increasing IL-2, IFN-gamma), and supports immune reconstitution. TP-5 has been used clinically in immunodeficiency states and as an adjunct in autoimmune conditions.

What the evidence actually shows

Grade B

Clinical use in immunodeficiency and rheumatoid arthritis with demonstrated immune improvement. Multiple studies confirm T-cell maturation enhancement. Approved in some countries for immunodeficiency.

Regulatory status

Status
Not approved in the United States (no Drugs@FDA record, no DailyMed SPL) and no current EMA authorisation located. Trade names Timunox, Sintomodulina and Immunox appear in PubChem's synonym list, indicating historical marketing outside the US; the corresponding authorisations could not be retrieved from a regulator source, so current marketing status in any specific country is unverified.
Clinical stage
ClinicalTrials.gov lists 10 registered studies (phases 1-3); no active late-stage Western development programme identified.
WADA
Not named on the WADA 2026 Prohibited List.
Source ↗

Pharmacokinetics

Half-life
30 min
Tmax
30 min
Absorption
subcutaneous
Elimination
renal
Washout
1 days
Low-confidence pharmacokinetics
These figures are recorded as clinical rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Dosing — what backs each figure

Thymopentin (TP-5, Timunox) has genuine published human dosing: 50 mg by injection three times weekly for 6-12 weeks in severe atopic dermatitis, across several randomised placebo-controlled trials from the 1980s-90s. It is not FDA-approved; it was marketed in some European markets, and no current FDA/EMA/MHRA label was retrievable.

ClinicalApproved labelling or a published human trial
PreclinicalAnimal studies — not a human dose

  • 1, 2 or 4 mg subcutaneously near the supramammary lymph node for 3 days; 4 mg optimal

    lactating dairy cows (subclinical mastitis) · subcutaneous · PMID 25976252

Animal doses do not convert to human doses by body weight alone. Route matters too — a compound dosed intraperitoneally in mice tells you little about subcutaneous use.

Handling and storage

No compound-specific stability data exists
No current FDA or EMA label exists (absent from Drugs@FDA and DailyMed), so no authoritative storage specification could be retrieved. The historical European product Timunox (Cilag) is no longer accessible as a label. No compound-specific stability data located in indexed literature. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

Contraindications
  • ·Not established

Injection-site reactions

References (3)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
storage.lyophilized, storage.reconstituted, storage.lightSensitive, reconstitution.solvent

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Healing & repair

BPC-157
A synthetic pentadecapeptide derived from a protein found in gastric juice. Studied for tissue repair, tendon/ligament healing, and gut protection in preclinical models.
BPC-157 Arginate
BPC-157 Arginate is the arginine salt form of Body Protection Compound 157, a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. This formulation pairs the BPC-157 peptide with arginine as a counter-ion, which proponents claim provides improved stability and enhanced oral bioavailability compared to the standard acetate salt form. The underlying peptide consists of 15 amino acids and has demonstrated cytoprotective, anti-inflammatory, and tissue-healing properties across numerous preclinical studies. It promotes angiogenesis, modulates nitric oxide pathways, and upregulates growth factor expression. The arginate form is marketed as offering better gastric survival and systemic absorption when taken orally, though direct head-to-head comparative data remains limited.
GV1001
A 16-amino acid peptide derived from the active site of human telomerase reverse transcriptase (hTERT). Originally developed as a cancer immunotherapy vaccine, now investigated for anti-inflammatory and anti-aging properties.